The Science
Who we are
We're Mikra — a group of world-renowned scientists, doctors, Olympic medalists, parents and chronic disease survivors from around the globe with one mission: engineer cellular therapeutics that increase the period of life spent in good health.
We are pushing biosciences beyond the expected and comfortable, by taking a pharmaceutical approach to supplements with the goal of increasing your healthspan.
Form follows function
We don't focus on fancy packaging, fairy dusting or trendy molecules. Instead, we focus on utilizing evidence-based bioactive compounds with a pharmaceutical-grade delivery system.
Our science isn't static — there are 91,472 PubMed publications around our bioactive compounds and delivery technology (and counting).



Consistent & effective dosage
Review the facts
We believe nutraceuticals that work like pharmaceuticals are the future of supplements.
Our products go through a rigorous research and development process to ensure your body receives evidence-backed ingredients that actually work.
Delivery directly to your cells
Mikra utilizes a patented, transferrin-mediated glycoprotein to ensure direct delivery into your cells through your jejunum (the second part of your small intestine).
Cellular Liposomes (20nm) are formed in our lab with our bioactive compounds and a liposomal:transferrin matrix which allows 100% passage through your digestive tract.
Testing, 1-2-3...
Independent Third Party Testing
The safety and efficacy of our products is prioritized above all else. We strive to ensure that
everything we do enhances the benefit to the end user, from our research, to our delivery systems and precise dosing.
Multi-omics data is key
Clinical Research
At Mikra, we’re focusing on functional genomics – for every product we launch, we look at how it affects you on a cellular level (genomics) by mapping which gene expression pathways are triggered (transcriptomics), positively and negatively. That way, we know that our product is actually affecting you positively at the most microscopic level: your cells.
Our clinical trial roadmap is structured to inform not only our product innovation and iterations, but also the industries of nutraceuticals and science in general. Upon conclusion, all of our data will be open-sourced and accessible to all.
Chronic Fatigue Syndrome/Myalgic encephalomyelitis is a complicated disorder characterized by extreme fatigue that lasts for at least six months and that can't be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity, but doesn't improve with rest.
Global population affected
> 78 Million People
Primary standard of care
NONE
Economic impact (USA)
Approximately $9.1 Billion ($20,000/person with CFS/ME)
Trial locale
Multisite, Decentralized
Chronic Fatigue Syndrome/Myalgic encephalomyelitis is a complicated disorder characterized by extreme fatigue that lasts for at least six months and that can't be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity, but doesn't improve with rest.
Global population affected
> 78 Million People
Primary standard of care
NONE
Economic impact (USA)
Approximately $9.1 Billion ($20,000/person with CFS/ME)
Trial locale
Multisite, Decentralized